Inactive Instrument

CytRx Corporation Share Price Nasdaq

Equities

US2328283013

Biotechnology & Medical Research

End-of-day quote Nasdaq
- USD - Intraday chart for CytRx Corporation
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2022 - Sales 2023 - Capitalization 6L 5.37Cr
Net income 2022 -40L -33Cr Net income 2023 - 0 EV / Sales 2022 -
Net cash position 2022 11.45L 9.56Cr Net cash position 2023 20.36L 17Cr EV / Sales 2023 -
P/E ratio 2022
-1.05 x
P/E ratio 2023
1.91 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 99.44%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 55 10/22/10
Director of Finance/CFO 72 01/07/01
Corporate Secretary - -
Members of the board TitleAgeSince
Chairman 55 29/21/29
Director/Board Member 64 27/22/27
Director/Board Member 69 12/17/12
More insiders
LadRx Corp is a biopharmaceutical research and development company specializing in oncology. The Company focuses on the discovery, research and clinical development of anti-cancer drug candidates that employ technologies that target chemotherapeutic drugs to solid tumors and reduce off-target toxicities. The Company’s linker activated drug release (LADR) technology platform consists of an organic backbone that is attached to a chemo toxic agent. The LADR backbone is to first target and deliver the chemo toxic agent to the tumor environment, and then to release the chemo toxic agent within the tumor. The LADR Technology offers the opportunity for multiple pipeline drugs. The LADR development efforts are focused on two classes of ultra-high potency albumin-binding drugs. These LADR-based drugs, LADRs 7, 8, 9, and 10, combine the proprietary LADR backbone with derivatives of the auristatin and maytansinoid drug classes.
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW